testing. Biomarkers serve multiple roles in oncology, into clinical outcomes such as disease recurrence, independent of treatment received. Predictive biomarkers, by contrast, enable the identification of oncology.4,5 Testing for predictive biomarkers can may not be effective or safe.6 Beyond prognostic and predictive utility, biomarkers are also used for regarding disease progression, patient safety, and the effectiveness of current treatment interventions.7 Notes: ALL = Acute Lymphoblastic Leukemia; AML= Acute Myeloid Leukemia; CML= Chronic Myeloid Leukemia; CLL/SLL = Chronic Lymphocytic Leukemia / 6 I Advancing Precision Oncology: Trends in Oncology Biomarker Testing in the U.s.